Subtopic Deep Dive
Multiple Endocrine Neoplasia Type 1
Research Guide
What is Multiple Endocrine Neoplasia Type 1?
Multiple Endocrine Neoplasia Type 1 (MEN1) is an autosomal dominant familial cancer syndrome caused by MEN1 gene mutations leading to tumors in parathyroids, enteropancreatic endocrine tissues, and anterior pituitary.
MEN1 affects multiple endocrine glands with high penetrance by age 50. Chandrasekharappa et al. (1997) cloned the MEN1 gene on chromosome 11q13 via positional cloning (2055 citations). Byström et al. (1990) mapped MEN1 to 11q13 using deletion mapping in tumors (298 citations). Over 1300 germline mutations identified.
Why It Matters
MEN1 genetic screening enables presymptomatic detection of parathyroid, pituitary, and pancreatic neuroendocrine tumors, guiding surveillance protocols that improve survival. Chandrasekharappa et al. (1997) enabled mutation-specific risk assessment for family members. Daly et al. (2006) revealed high pituitary adenoma prevalence (1:1065 in Liege), underscoring need for population screening in MEN1 kindreds. Beckers et al. (2013) highlighted familial pituitary adenomas linked to MEN1/AIP, informing tailored therapies that reduce morbidity from aggressive tumors.
Key Research Challenges
Genotype-Phenotype Correlations
MEN1 mutations show variable expressivity; no clear links between mutation type and tumor phenotype exist. Chandrasekharappa et al. (1997) identified diverse mutations but penetrance varies widely. Larger cohorts needed for statistical correlations.
Pituitary Tumor Surveillance
Pituitary adenomas in MEN1 often aggressive and prolactin-secreting, resisting medical therapy. Daly et al. (2010) reported poor somatostatin analog response in AIP-related cases, relevant to MEN1 overlap. Optimal MRI/prolactin monitoring intervals unclear.
Pancreatic NET Management
Enteropancreatic tumors progress to malignancy in 30-70% of MEN1 cases. Ayala-Ramirez et al. (2010) identified tumor size/location as metastasis predictors, applicable to MEN1-NETs. Prophylactic strategies lack randomized trial evidence.
Essential Papers
Positional Cloning of the Gene for Multiple Endocrine Neoplasia-Type 1
Settara C. Chandrasekharappa, Siradanahalli C. Guru, Pachiappan Manickam et al. · 1997 · Science · 2.1K citations
Multiple endocrine neoplasia–type 1 (MEN1) is an autosomal dominant familial cancer syndrome characterized by tumors in parathyroids, enteropancreatic endocrine tissues, and the anterior pituitary....
High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liege, Belgium
Adrian Daly, Martine Rixhon, Christelle Adam‐Guillermin et al. · 2006 · The Journal of Clinical Endocrinology & Metabolism · 1.0K citations
Abstract Context: Prevalence data are important for assessing the burden of disease on the health care system; data on pituitary adenoma prevalence are very scarce. Objective: The objective of the ...
Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators
Montserrat Ayala‐Ramirez, Lei Feng, Marcella M. Johnson et al. · 2010 · The Journal of Clinical Endocrinology & Metabolism · 416 citations
The size and location of the primary tumor were significant clinical risk factors for metastasis and decreased overall survival duration. These findings delineate the follow-up and treatment for th...
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line<i>AIP</i>Mutations and Pituitary Adenomas: An International Collaborative Study
Adrian Daly, María A. Tichomirowa, Patrick Pétrossians et al. · 2010 · The Journal of Clinical Endocrinology & Metabolism · 361 citations
AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that e...
Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas
Jenny Welander, Peter Söderkvist, Oliver Gimm · 2011 · Endocrine Related Cancer · 346 citations
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine tumors of the adrenal glands and the sympathetic and parasympathetic paraganglia. They can occur sporadically or as a part...
Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene
Albert Beckers, Lauri A. Aaltonen, Adrian Daly et al. · 2013 · Endocrine Reviews · 337 citations
Abstract Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approximately 1:1000 in the developed world. Pituitary adenomas have a serious disease bu...
Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years
Oksana Hamidi, William F. Young, Nicole M. Iñiguez‐Ariza et al. · 2017 · The Journal of Clinical Endocrinology & Metabolism · 302 citations
Abstract Context Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and knowledge of the natural history is limited. Objective We aimed to describe baseline characteristics and outc...
Reading Guide
Foundational Papers
Start with Chandrasekharappa et al. (1997) for MEN1 gene cloning (2055 citations), then Byström et al. (1990) for mapping, followed by Daly et al. (2006) for pituitary prevalence in MEN1 context.
Recent Advances
Beckers et al. (2013) on familial pituitary adenomas and MEN1/AIP; Ayala-Ramirez et al. (2010) on NET prognostic factors applicable to MEN1 pancreatics.
Core Methods
Positional cloning (Chandrasekharappa 1997), deletion mapping (Byström 1990), cross-sectional prevalence studies (Daly 2006), germline mutation sequencing.
How PapersFlow Helps You Research Multiple Endocrine Neoplasia Type 1
Discover & Search
Research Agent uses searchPapers('MEN1 pituitary adenomas surveillance') to find Chandrasekharappa et al. (1997), then citationGraph reveals 2055 downstream papers on genotype-phenotype; exaSearch uncovers obscure MEN1 protocols while findSimilarPapers links to Daly et al. (2006) prevalence data.
Analyze & Verify
Analysis Agent applies readPaperContent on Chandrasekharappa et al. (1997) to extract mutation spectra, verifyResponse(CoVe) cross-checks prevalence claims against Daly et al. (2006), and runPythonAnalysis computes survival meta-analysis from Ayala-Ramirez et al. (2010) cohorts with GRADE grading for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in MEN1 surveillance protocols via contradiction flagging between Byström et al. (1990) mapping and modern cohorts; Writing Agent uses latexEditText for review drafting, latexSyncCitations for 10+ MEN1 papers, latexCompile for figure-ready PDF, and exportMermaid for genotype-phenotype flowcharts.
Use Cases
"Run survival analysis on MEN1 pancreatic NET tumor sizes from literature"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis(pandas meta-analysis of Ayala-Ramirez et al. 2010 sizes) → matplotlib Kaplan-Meier plot output.
"Draft MEN1 surveillance protocol review with citations and flowchart"
Synthesis Agent → gap detection → Writing Agent → latexEditText(protocol LaTeX) → latexSyncCitations(Daly 2006, Chandrasekharappa 1997) → latexCompile → exportMermaid(flowchart).
"Find GitHub repos analyzing MEN1 mutation databases"
Research Agent → paperExtractUrls(Chandrasekharappa 1997) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis(local clone stats).
Automated Workflows
Deep Research workflow scans 50+ MEN1 papers via searchPapers → citationGraph → structured report on pituitary surveillance gaps with GRADE scores. DeepScan's 7-step chain verifies Chandrasekharappa et al. (1997) claims against Byström et al. (1990) using CoVe checkpoints. Theorizer generates MEN1 prophylactic hypotheses from Daly et al. (2006) prevalence linked to Beckers et al. (2013) genetics.
Frequently Asked Questions
What defines Multiple Endocrine Neoplasia Type 1?
MEN1 is an autosomal dominant syndrome from MEN1 gene mutations causing parathyroid, pancreatic, and pituitary tumors (Chandrasekharappa et al., 1997).
What are key methods for MEN1 gene discovery?
Positional cloning identified MEN1 on 11q13 (Chandrasekharappa et al., 1997, 2055 citations); deletion mapping confirmed location (Byström et al., 1990, 298 citations).
What are seminal MEN1 papers?
Chandrasekharappa et al. (1997, Science, 2055 citations) cloned MEN1; Daly et al. (2006, 1023 citations) quantified pituitary adenoma prevalence relevant to MEN1 screening.
What open problems exist in MEN1 research?
Genotype-phenotype correlations unclear; optimal pituitary surveillance timing unknown; prophylactic pancreatic NET strategies lack trials (Ayala-Ramirez et al., 2010).
Research Pituitary Gland Disorders and Treatments with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Multiple Endocrine Neoplasia Type 1 with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.